National Institutes of Health (NIH)
Bethesda
MD
United States
169 articles with National Institutes of Health (NIH)
-
The U.S. National Institutes of Health (NIH) is launching a clinical trial of a combination of Gilead Sciences’ antiviral drug remdesivir (Vitrakvy) and hyperimmune intravenous immunoglobulin (hIVIG).
-
Ellume Secures $30M from National Institutes of Health RADx Initiative to Accelerate Development of Rapid COVID-19 DiagnosticsThe company will launch three rapid COVID-19 testing products in the U.S.
10/6/2020
Ellume , the company reimagining digital diagnostics, today announced a $30 million Phase 2 award from the U.S. National Institutes of Health (NIH)’s Rapid Acceleration of Diagnostics (RADx) initiative to accelerate the clinical testing and manufacturing of three COVID-19 antigen tests. The RADx initiative rigorously reviews and selects innovative, highly accurate diagnostic technologies to move quickly through the development pipeline t
-
The U.S. National Institutes of Health (NIH) awarded seven companies and academic institutions grants to develop digital health technology to help with the COVID-19 pandemic.
-
Ginkgo Bioworks Awarded $40MM NIH RADx-ATP Contract to Expand High Throughput SARS-CoV-2 Testing
7/31/2020
Funding will enable expansion of automated Bioworks facility for large scale suppression testing using next generation sequencing
-
The Phase II study will be performed in collaboration with the National Institutes of Health under a $2.7 million grant.
-
Andor Health Platform to Accelerate Clinical Research Team Collaboration and Communication at National Institutes of Health
4/8/2020
Andor Health's ThinkAndor™ platform to push critical notifications to NIH Clinical Center teams, providers and patients, while increasing overall operational efficiency
-
The U.S. National Institutes of Health announced that a Phase II clinical trial of AstraZeneca and Merck’s selumetinib in neurofibromatosis type 1 shrank inoperable tumors.
-
The focus of the research will be to learn more about ApoE4 and how and why it affects Alzheimer’s disease.
-
Windgap Medical and University of Minnesota Twin Cities Receive $3.2 Million NIH Grant to Develop Cyanide Antidote Autoinjector
1/15/2020
Under the grant, researchers from the University's Center for Drug Design, College of Pharmacy, and Massachusetts-based pharmaceutical company Windgap Medical are collaborating to design an autoinjector.
-
Instead of injecting the vaccine into the muscle or skin, researchers injected BCG directly into the bloodstream. The results were dramatically improved effectiveness.
-
ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention
11/21/2019
Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV into healthy cells.
-
CorTechs Labs Enters Phase 2 of $1.15 Million NIH Grant to Automate the Diagnosis and Prediction of Alzheimer’s Disease
11/7/2019
Phase two of this grant proves CorTechs Labs’ PETQuant™ to be clinically and commercially viable
-
Neuronoff Receives $2.2 Million Grant From National Institutes of Health to Combat Opioid Abuse
10/31/2019
The Injectrode™ cures inside the body and is molded to the shape of the specific target.
-
EicOsis Awarded SBIR Grant from the NCI/NIH to Evaluate the Potential of Drug Candidate, EC5026, to Treat Cancer-associated Pain
10/30/2019
EC5026 is an orally active potent small molecule that has been shown to be highly efficacious for pain relief of both inflammatory and neuropathic pain in a variety of animal species.
-
Molecular Targeting Technologies, Inc. Receives Global Rights From NIH for Integrin-Targeting Radiotherapeutics to Treat GBM and Lung Cancer
10/28/2019
The key feature of this technology is the incorporation of a derivative of Evans Blue into RGD peptide radiopharmaceutical which binds to both albumin and integrin thus extends residence time, enabling smaller and less frequent dosing.
-
The organizations hope the funding will result in clinical trials in the U.S. and countries in sub-Saharan Africa in the next seven to 10 years. Francis Collins, director of the NIH, said they would focus on “access, scalability and affordability.”
-
BlueWillow Receives FDA Clearance to Begin Phase 1 Study of its Intranasal Anthrax Vaccine
10/23/2019
The Phase 1 clinical study is expected to begin enrollment this year and is being funded by the National Institute of Allergy and Infectious Diseases, an institute within the National Institutes of Health
-
Amygdala Neurosciences Awarded $1.35 million NIH Grant to Conduct Long Term, Phase 3 Enabling, Toxicology Studies
10/21/2019
ANS-6637, which is in Phase 2 clinical development, is a new chemical entity selective ALDH2 Inhibitor with a mechanism of action expected to prevent craving and relapse for patients being treated for substance use disorders.
-
Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma
10/17/2019
Rafael will provide the compound for the study.